Food News and Research

RSS

Tips to combat childhood obesity

You've heard the alarming statistic before: one-third of U.S. children and teens are overweight or obese, increasing their risk of developing health problems such as diabetes.

23 Jan 2010

Recent releases in global health

"Picture the situation in Haiti: families living on top of sewage-contaminated rubbish dumps, with no reliable sources of food and water and virtually no access to health care. This scenario depicts the situation in Haiti before the earthquake that catapulted this impoverished and conflict-ridden country into the international headlines,"

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

FDA approves fampridine-SR drug for treatment of multiple sclerosis

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease - and their efforts helped pave the way for today's action by the FDA.

23 Jan 2010

Ampyra receives FDA approval for improving walking in MS patients

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

23 Jan 2010

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

Biovail Corporation today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail’s FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva’s generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009.

22 Jan 2010

Aid flow to Haiti improves as seaport opens, airport volume dramtically increases

Nine days after a major earthquake struck, "deeply needed aid streamed into Haiti's ravaged capital in quantities that relief agencies said is a clear sign of progress," the Miami Herald reports.

22 Jan 2010

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010

St. John Ambulance to send first aid and emergency medical care experts to Jacmel

In response to the dire need for emergency humanitarian aid in Haiti, St. John Ambulance is sending an initial team of first aid and emergency medical care experts to Jacmel. The team is expected to leave Montreal by the end of the month. This first team's assessment of local needs will be used to plan the long-term deployment of subsequent teams. Teams will be deployed and supervised from Montreal.

22 Jan 2010

Elsevier announces the winners of Asian Young Women Researcher Awards

Elsevier announced today the winners of the Asian Young Women Researcher Awards, a joint development between its flagship product Scopus(R), the world's largest abstract and citation database of peer-reviewed literature and the Third World Organisation for Women in Science (TWOWS) and TWAS, the academy of sciences for the developing world.

22 Jan 2010

Catholic Charities USA convenes Centennial Summit in San Antonio

Catholic Charities USA, the 170-member national human services organization committed to cutting poverty in half by 2020–hosted by Catholic Charities, Archdiocese of San Antonio, Inc. and joined by Catholic Charities agencies from around the region–convened one of 10 Centennial Summits in San Antonio today as part of the organization's 100 year history.

22 Jan 2010

Long-term health effects of e-cigarettes: More research needed

The need for more research into the long-term health effects of electronic cigarettes has been highlighted by scientists in the British Medical Journal.

22 Jan 2010

TGen holds the promise of a brighter economic future for Scottsdale

TGen Drug Development (TD2) is poised to play a significant role in the expansion of Scottsdale's biomedical industry, fostering new jobs and city revenues, and prompting the creation of more related businesses.

22 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

Pioneering research explores possibility of developing mineral enriched flour

Pioneering research combining plant breeding and high-intensity x-rays is being used by scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) to explore the possibility of developing wheat which could be used to make potentially life-saving mineral enriched flour.

22 Jan 2010

Companies across the United States to donate millions of dollars to support Haiti earthquake victims

Companies large and small, representing industries across the United States, have taken action to support their neighbors in Haiti by donating millions of dollars to the American Red Cross and by encouraging their customers and employees to follow suit.

22 Jan 2010

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells.

22 Jan 2010

Understanding mechanism of SIRT6 activity may help treat diabetes and cancer

A study investigating how a cellular enzyme affects blood glucose levels in mice provides clues to pathways that may be involved in processes including the regulation of longevity and the proliferation of tumor cells.

22 Jan 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

Update on the status of Somaxon Pharmaceuticals' NDA for Silenor provided

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

22 Jan 2010